Primary Cervical Dystonia (Trihexyphenidyl)

PreclinicalSmall molecule

Primary Cervical Dystonia (Trihexyphenidyl) is one of 5 small molecule programs targeting Dystonia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DystoniaActive, not recruiting

DystoniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Dystonia

#DrugCompanyPhaseTrials

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

—2

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Preclinical

1 3

Botulinum Toxins

YYale University

Preclinical

1 4

Primary Cervical Dystonia (Trihexyphenidyl)

UUniversity of Florida

Preclinical

1 5

FP-TZTP

NNational Institute of Mental Health (NIMH)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dystonia1 trial

Neuroimaging of Dystonia

Completed·UUniversity of Florida··NCT02046447·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Primary Cervical Dystonia (Trihexyphenidyl). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Primary Cervical Dystonia (Trihexyphenidyl) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Primary Cervical Dystonia (Trihexyphenidyl). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Florida

Primary Cervical Dystonia (Trihexyphenidyl)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dystonia1 trial

References

Drug Info

Quick Facts

Related News